ARFONAD Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Arfonad, and when can generic versions of Arfonad launch?
Arfonad is a drug marketed by Roche and is included in one NDA.
The generic ingredient in ARFONAD is trimethaphan camsylate. Additional details are available on the trimethaphan camsylate profile page.
Summary for ARFONAD
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 2 |
Patent Applications: | 538 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ARFONAD at DailyMed |
US Patents and Regulatory Information for ARFONAD
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Roche | ARFONAD | trimethaphan camsylate | INJECTABLE;INJECTION | 008983-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |